Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11207 for the treatment of Parkinson's disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
Часто задаваемые вопросы
В каком секторе работает Aeolus Pharmaceuticl (AOLS)?
Aeolus Pharmaceuticl относится к сектору Здравоохранение.
Какова текущая цена акций Aeolus Pharmaceuticl (AOLS)?
По последним данным, цена акций Aeolus Pharmaceuticl составляет 0,00 $, предыдущее закрытие — 0,00 $.
Выплачивает ли Aeolus Pharmaceuticl (AOLS) дивиденды?
Нет, Aeolus Pharmaceuticl не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Aeolus Pharmaceuticl (AOLS)?
У компании Aeolus Pharmaceuticl бета -64.364, что указывает на более низкую волатильность по сравнению с рынком в целом.
